Aurinia Pharmaceuticals Aktie [WKN DE: A1W7D4 / ISIN: CA05156V1022]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Aurinia Pharmaceuticals Inc

30.04.22		ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH (PR Newswire)
21.04.22		ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AUPH (PR Newswire)
19.04.22		Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis (Businesswire)
04.04.22		Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings (Businesswire)
27.03.22		AUPH INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation - AUPH (PR Newswire)
15.03.22		ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation - AUPH (PR Newswire)
03.03.22		Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences (Businesswire)
28.02.22		Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates (Businesswire)
03.02.22		Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference (Businesswire)
09.12.21		Pre-market Movers: ENSC, RETA, CCNC, PEAR, SYTA… (RTTNews)
22.11.21		Pre-market Movers: ASTR, VG, CEI, CMBM, PTNR… (RTTNews)
17.08.21		Aurinia Pharmaceuticals Declines 9% Following Acquisition Of Two Pipeline Assets (RTTNews)
30.06.21		Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs (Businesswire)
25.06.21		Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA) (Businesswire)
14.06.21		Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors (Businesswire)
27.05.21		Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference (Businesswire)
20.05.21		Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis (Businesswire)
14.05.21		Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences (Businesswire)
10.05.21		Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis (Businesswire)
10.05.21		Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet (Businesswire)
06.05.21		Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights (Businesswire)
28.04.21		Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021 (Businesswire)
15.04.21		Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference (Businesswire)
08.04.21		Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings (Businesswire)
15.03.21		Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report (Businesswire)
02.03.21		Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences (Businesswire)
24.02.21		Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights (Businesswire)
18.02.21		Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference (Businesswire)
17.02.21		Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021 (Businesswire)
23.01.21		FDA Approves Aurinia Pharma's Lupkynis - Second Lupus Nephritis Drug In A Month (RTTNews)
23.01.21		FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis (Businesswire)
22.01.21		Pre-market Movers In Healthcare Sector: ADMP, FLDM, ATOS, AUPH, SENS... (RTTNews)
11.01.21		Will Aurinia Pharma's Lupus Nephritis Drug Pass FDA Muster? (RTTNews)
08.01.21		Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences (Businesswire)
29.12.20		Biotech Stocks Facing FDA Decision In January 2021 (RTTNews)
17.12.20		Aurinia gibt Kooperations- und Lizenzvertrag mit Otsuka Pharmaceutical Co., Ltd. über die Entwicklung und Vermarktung von Voclosporin in Europa und Japan bekannt (Businesswire)
17.12.20		Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan (Businesswire)
15.12.20		Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity (Businesswire)
02.12.20		Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference (Businesswire)
20.11.20		Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
12.11.20		Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference (Businesswire)
10.11.20		Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights (Businesswire)
09.11.20		Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020 (Businesswire)
03.11.20		AUPH's Dry Eye Syndrome Study Fails, KPTI's SEAL Study Hits Goal, REGN Halts Rare Bone Disease Trial (RTTNews)
02.11.20		Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome (Businesswire)
28.10.20		AUPH Initiates VOCOVID Trial, KALA Gets FDA Nod, NVAX Expands COVID-19 Vaccine Study Size In UK (RTTNews)
27.10.20		Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19 (Businesswire)
22.10.20		Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020 (Businesswire)
14.10.20		Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com (Businesswire)
02.10.20		Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Auric Minerals-Aktie: Kurssturz wegen neuem Vertrag?

KTM: Auszahlung offener Gehälter und Löhne ist angelaufen - KTM-Mutter Pierer Mobility-Aktie höher

NVIDIA & Co.: Bernstein sieht diese drei KI-Aktien als Top-Chancen für 2025

voestalpine-Aktie steigt dennoch: voestalpine-Vorstände zahlten 100.000 Euro Boni zurück

US-Inflationsdaten sorgen für Ausschläge: Kräftiges Plus an der Wall Street -- ATX weit im Plus -- DAX nach neuem Allzeithoch mit Rekord-Schluss -- Asiens Märkte beenden Handel überwiegend leichter

Pro-Bitcoin-Präsident? Trump könnte Bitcoin zur Reservewährung machen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	17.01.2025 07:35
Kaufwert:	EUR
	Hinzufügen Speichern